Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer, for the month of March 2019. The report was signed on March 22, 2019, by Eyal Leibovitz, Chief Financial Officer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is a corporate governance update:
- On March 20, 2019, Dr. Ruth Ben Yakar resigned as a director of Cellect Biotechnology Ltd., effective immediately.
- The resignation was to allow her to focus on other responsibilities.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Dr. Ben Yakar's resignation.
- Confirm if the resignation impacts ongoing clinical trials or strategic partnerships.
- Review subsequent filings for any financial updates, as this 6-K contains no financial data.